Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2091]

CAPTIVATE: Fixed-duration first-line treatment with ibrutinib plus venetoclax...

Dr Rajat Bannerji - Rutgers Cancer Institute of New Jersey/RWJBarnabas Health...

CAPTIVATE: Fixed-duration first-line treatment with ibrutinib plus venetoclax for CLL/SLL ( Dr Rajat Bannerji - Rutgers Cancer Institute of New Jersey/RWJBarnabas Health, New Jersey, USA )

CHRONOS: Anti-EGFR rechallenge therapy with panitumumab driven by ctDNA...

Prof Andrea Sartore-Bianchi - Ospedale Niguarda, Milan, Italy

CHRONOS: Anti-EGFR rechallenge therapy with panitumumab driven by ctDNA molecular selection in mCC ( Prof Andrea Sartore-Bianchi - Ospedale Niguarda, Milan, Italy )

CodeBreaK100: Sotorasib in pretreated KRAS p.G12C mNSCLC

Dr Ferdinandos Skoulidis - MD Anderson Cancer Center, Houston, USA

CodeBreaK100: Sotorasib in pretreated KRAS p.G12C mNSCLC ( Dr Ferdinandos Skoulidis - MD Anderson Cancer Center, Houston, USA )

LEAP-004: Lenvatinib + pembrolizumab for patients with advanced melanoma and...

Dr Ana Arance - Hospital Clínic de Barcelona, Barcelona, Spain

LEAP-004: Lenvatinib + pembrolizumab for patients with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor ( Dr Ana Arance - Hospital Clínic de Barcelona, Barcelona, Spain )

OncoAlert and ecancer ASCO roundup - Day 3

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer ASCO roundup - Day 3 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

PANAMA: Maintenance 5FU/LV plus panitumumab or 5FU/LV alone in RAS wildtype mCRC

Prof Dominik Modest - Charité Universitätsmedizin Berlin, Berlin, Germany

PANAMA: Maintenance 5FU/LV plus panitumumab or 5FU/LV alone in RAS wildtype mCRC ( Prof Dominik Modest - Charité Universitätsmedizin Berlin, Berlin, Germany )

OncoAlert and ecancer ASCO roundup - Day 2

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer ASCO roundup - Day 2 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

OncoAlert and ecancer ASCO roundup - Day 1

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer ASCO roundup - Day 1 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

Amivantamab in combination with lazertinib for osimertinib-relapsed, chemo...

Dr Joshua Sabari and Dr Anna Minchom

Amivantamab in combination with lazertinib for osimertinib-relapsed, chemo-naïve EGFRm NSCLC ( Dr Joshua Sabari and Dr Anna Minchom )

Bemarituzumab with FOLFOX6 in FGFR2b+ advanced gastric/gastroesophageal...

Prof Daniel Catenacci - University of Chicago, Chicago, USA

Bemarituzumab with FOLFOX6 in FGFR2b+ advanced gastric/gastroesophageal junction adenocarcinoma ( Prof Daniel Catenacci - University of Chicago, Chicago, USA )

mCRPC: Latest developments in diagnostics and combination therapies

Dr Eleni Efstathiou, Prof Fred Saad and Prof Oliver Sartor

mCRPC: Latest developments in diagnostics and combination therapies ( Dr Eleni Efstathiou, Prof Fred Saad and Prof Oliver Sartor )

Long term outcome of enfortumab vedotin + pembrolizumab in first line locally...

Dr Terence Friedlander - UCSF, San Francisco, USA

Long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma ( Dr Terence Friedlander - UCSF, San Francisco, USA )

More from ecancer